01061.HK
Essex Bio-Technology Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.21
+3.76%Year over year
Reported trailing growth
- Revenue
- +8.7%
- EBITDA
- +12.4%
- EBIT
- +10.6%
- EPS
- +10.9%
- Free cash flow
- +10.6%
- Operating cash flow
- +5.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +11.2%
- EBITDA
- +14.3%
- EBIT
- +10.5%
- Net income
- +12.2%
- EPS
- +12.8%
- Free cash flow
- +9.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026